Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease.

Autor: Sun W; Takeda Development Center Americas, 40 Landsdowne St, Cambridge, MA, 02139, USA., Fennimore B; Division of Gastroenterology and Hepatology, University of Colorado, Aurora, CO, USA., Beaulieu DB; Vanderbilt University Medical Center, Nashville, TN, USA., Arsenescu R; AHS Hospital Corporation, Morristown Medical Center, Morristown, NJ, USA., Stein AC; Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL, USA., Chen J; Takeda Development Center Americas, 40 Landsdowne St, Cambridge, MA, 02139, USA., Lin T; Integrated Drug Development, Certara, Princeton, NJ, USA., McKnight S; Takeda Development Center Americas, 40 Landsdowne St, Cambridge, MA, 02139, USA., Kadali H; Takeda Development Center Americas, 40 Landsdowne St, Cambridge, MA, 02139, USA., Rosario M; Takeda Development Center Americas, 40 Landsdowne St, Cambridge, MA, 02139, USA., Lirio RA; Takeda Development Center Americas, 40 Landsdowne St, Cambridge, MA, 02139, USA. Richard.Lirio@takeda.com.
Jazyk: angličtina
Zdroj: Clinical pharmacokinetics [Clin Pharmacokinet] 2021 Jun; Vol. 60 (6), pp. 811-818. Date of Electronic Publication: 2021 Feb 05.
DOI: 10.1007/s40262-021-00985-4
Abstrakt: Background and Objectives: The safety of inflammatory bowel disease medications during lactation is of significant relevance to women of childbearing potential. Available data regarding the transfer of biologic agents for inflammatory bowel disease via breast milk are limited to case reports. The objective of this prospective postmarketing lactation study was to assess vedolizumab concentrations in breast milk from lactating vedolizumab-treated women with inflammatory bowel disease.
Methods: Breast milk was serially collected throughout the dosing interval from 11 patients receiving established intravenous vedolizumab 300-mg maintenance therapy every 8, 6, or 4 weeks. Maternal safety was also assessed.
Results: Vedolizumab was detectable in ~90% of milk samples collected from all patients. Following the day 1 dose, vedolizumab milk concentrations increased with a median of 3-4 days to peak concentration, and subsequently decreased exponentially. For the nine patients receiving vedolizumab every 8 weeks, the average relative infant dose was 20.9%. Using a mean trough serum concentration of 11.2 µg/mL from historical studies, the ratio of mean vedolizumab milk-to-serum concentration was ~ 0.4 to 2.2%, consistent with published data on vedolizumab and other monoclonal antibody therapeutics for inflammatory bowel disease. The maternal safety profile was similar to that observed in previous vedolizumab studies. Published vedolizumab studies also showed no adverse findings for infants breastfed by vedolizumab-treated mothers.
Conclusions: Vedolizumab was present in human breast milk at a low level. The decision to use vedolizumab should balance the benefit of therapy to the mother and the potential risks to the infant.
Trial Registration: ClinicalTrials.gov, NCT02559713; registered 24 September, 2015.
Databáze: MEDLINE
Externí odkaz: